Related Experiment Video

Updated: Sep 9, 2025

Author Spotlight: Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning
14:47

Author Spotlight: Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning

Published on: April 21, 2023

2.9K

Reply: "Improving the Study of Impulse Control Disorders in CSAI-Treated Parkinson's Disease: Methodological and

Clément Desjardins1, Paulo André Dias Bastos2, Margherita Fabbri2

  • 1Department of Neurology, Rothschild Foundation Hospital, Paris, France.

Movement Disorders Clinical Practice
|September 2, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Parkinson's diseasecontinuous subcutaneous apomorphine infusionimpulse control disorders

More Related Videos

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

Related Experiment Videos

Last Updated: Sep 9, 2025

Author Spotlight: Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning
14:47

Author Spotlight: Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning

Published on: April 21, 2023

2.9K
Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702

Articles linked to this work by shared authors, journal, and citation graph.

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026

Diagnostic Accuracy of Exchangeable Copper for Grading the Severity of Wilson Disease.

Journal of inherited metabolic disease·2026

Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Insights From a Real-World Cohort.

Journal of movement disorders·2026

Poor outcome increase with baseline severity of lateral striatocapsular hemorrhages.

Journal of the neurological sciences·2025

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).

Movement disorders : official journal of the Movement Disorder Society·2025

Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study (iCARE-PD).

Movement disorders : official journal of the Movement Disorder Society·2025

Clinically Probable REM Sleep Behavior Disorder and Other Non-Motor Symptoms in Progressive Supranuclear Palsy: Prevalence and Associated Clinical Features.

Movement disorders clinical practice·2026

Interrater and Intrarater Reliability of the TWSTRS-Delphi Motor Severity Scale for Cervical Dystonia.

Movement disorders clinical practice·2026

How Do Oral Medications, Botulinum Toxin Use, and Treatment Burden Change after Deep Brain Stimulation for Dystonia?

Movement disorders clinical practice·2026

Breathe, Eat, Talk: Three Essential Ingredients to Quality-of-Life Outcomes in Movement Disorders.

Movement disorders clinical practice·2026

Comparative Analysis of L-Dopa and Deep Brain Stimulation on Bradykinesia Components in Parkinson's Disease.

Movement disorders clinical practice·2026

Multi-Domain Gait Profiling in Idiopathic Normal Pressure Hydrocephalus: Differentiating Fall Patterns and Assessing Shunt Responsiveness.

Movement disorders clinical practice·2026

Antidepressant effects of facial botulinum toxin a injections: Insights from randomized controlled trials.

Journal of affective disorders·2026

Incubation of cocaine craving is associated with reduced context-induced Fos expression in parvalbumin interneurons in the nucleus accumbens core of male rats.

Neuroscience·2026

Long-term safety of steroid-sparing immunosuppression in uveitis.

Current opinion in ophthalmology·2026

Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis.

Kidney international reports·2026

Calcium Crystal Deposits in Kidney Allografts: The Interplay of PTH Levels and Phosphaturia.

Kidney medicine·2026

Less Invasive Rapid Tranquilization in LMIC Emergency Settings: Comparison of Oral Risperidone Plus Clonazepam Versus Intramuscular Haloperidol in a Randomized Trial.

The International journal of social psychiatry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us